

Additional file 4: Detailed endoscopic outcomes

Study # condition duration	Methods	Dosing regimen, numbers of patients	Gastroduodenal ulcers	Ulcers with aspirin	Ulcers without aspirin	Comment
<b>C-021</b> OA 12 weeks	Endoscopy at baseline and 12 weeks (or early termination) Washout: NSAID/analgesic 48 hrs Piroxicam/oxaprozin 4 days Investigational drug 30 days	Cele [1] 2x50mg/day (n=258) Cele [2] 2x100mg/day (n=239) Cele [3] 2x200mg/day (n=237) Naprox 2x500mg/day (n=233) Plac (n=247)	Cele [1] 8/233 Cele [2] 7/227 Cele [3] 13/221 Naprox 34/210 Plac 5/217	Cele [1] 3/28 Cele [2] 1/31 Cele [3] 5/33 Naprox 5/36 Plac 2/33	Cele [1] 5/205 Cele [2] 6/196 Cele [3] 8/188 Naprox 29/174 Plac 3/184	Endoscopy data not available for all patients
<b>C-022</b> RA 12 weeks	Endoscopy at baseline and 12 weeks Washout: NSAID 48 hrs Analgesic 24 hrs Piroxicam/oxaprozin 4 days Investigational drug 30 days	Cele [1] 2x100mg/day (n=240) Cele [2] 2x200mg/day (n=235) Cele [3] 2x400mg/day (n=217) Naprox 2x500mg/day (n=225) Placebo (n=231)	Cele [1] 9/223 Cele [2] 6/219 Cele [3] 8/197 Naprox 37/210 Placebo 4/200	Cele [1] 0/23 Cele [2] 2/21 Cele [3] 1/15 Naprox 0/16 Placebo 0/16	Cele [1] 9/200 Cele [2] 4/198 Cele [3] 7/182 Naprox 37/194 Placebo 4/184	Endoscopy data not available for all patients
<b>C-062</b> OA/RA 12 weeks	Endoscopy at baseline, 4, 8, 12 weeks Washout: Investigational drug 30 days	Cele 2x200mg/day (n=269) Naprox 2x500mg/day (n=267)	Cele 20/269 Naprox 89/267	Cele 7/29 Naprox 12/28	Cele 11/182 Naprox 75/186	Aspirin status not available for all patients
<b>C-071</b> OA/RA 12 weeks	Endoscopy at baseline, 4, 8, 12 weeks Washout: Investigational drug (as daily therapy) 30 days	Cele 2x200mg/day (n=365) Diclo 2x75mg/day (n=387) Ibu 3x800mg/day (n=345)	Cele 400 25/356 Diclo 36/372 Ibu 78/334	Cele 2/36 Diclo 8/32 Ibu 12/41	Cele 23/258 Diclo 28/274 Ibu 66/235	Endoscopy data not available for all patients Aspirin status not available for all patients
<b>C-041</b> RA 24 weeks	Endoscopy at 24 weeks Washout: not specified	Cele 2x200mg/day (n=326) Diclo SR 2x75mg/day (n=329)	Cele 8/212 Diclo 33/218	no data	no data	Not all patients had endoscopy - depended on feasibility at the site
<b>C-849</b> (C-105, 106, 107 pooled) OA/RA 12 weeks	Endoscopy at baseline and 12 weeks Washout: Investigational drug 30 days	Cele 2x100mg/day (n=440) Diclo 2x50mg/day (n=440)	Cele 11/398 Diclo 20/390	Cele 0/7 Diclo 1/11	Cele 11/390 Diclo 19/378	Endoscopy data not available for all patients

Exclusions: Active GI disease [all]; treatment for UGI ulcer within 30 days [C-021, 022, 062, 071]; ulcer (3mm diam) at baseline [C-021, 022, 849, 062, 071]; >10 erosions in stomach or duodenum at baseline [C-021, C-022]

Cele = celecoxib; Diclo = diclofenac; GI = gastrointestinal; Ibu = ibuprofen; Naprox = naproxen; NSAID = nonsteroidal anti-inflammatory drug; Plac = placebo; UGI = upper gastrointestinal.